The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular events by 14% in people with type 2 diabetes and heart or kidney disease. ️ The ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Female semaglutide users had more than a two-fold higher risk for hair loss than users of bupropion-naltrexone.